A phase 3, randomized, double-blind, placebo-controlled study evaluating the efFicacy and safely or idelalisib (GS-1101) in combination with bendamustine and Minimal) for previously treated chronic lymphocytic leukemia (CLL).
2014
Keywords:
- Correction
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI